Followers | 696 |
Posts | 31842 |
Boards Moderated | 8 |
Alias Born | 03/16/2014 |
Wednesday, October 18, 2017 12:49:35 PM
MONCTON, New Brunswick, Oct. 12, 2017 (GLOBE NEWSWIRE) -- Organigram Holdings Inc. (TSX VENTURE:OGI) (OTCQB:OGRMF) (the “Company” or “Organigram”), a leading licensed producer of medical marijuana based in Moncton, New Brunswick, is pleased to announce that it has initiated the process for re-certification as an organic producer of cannabis in Canada with ECOCERT Canada.
Organigram is currently undergoing a significant expansion of its facility to meet the growing needs of our business. In order to meet the anticipated demand for both mineral and organic production, the company has reconfigured their existing cultivation space and are in the process of building new areas devoted only to organic production.
As part of the process, Organigram submitted a comprehensive action plan to ECOCERT Canada, part of the Ecocert group, one of the largest organic certification organizations in the world, outlining the company’s approach to the growing and segregation of both product lines. The plan is designed to ensure the integrity of organic products within their facility, and was approved by ECOCERT Canada in September 2017.
The re-certification process continues with a series of onsite inspections. These inspections will review the cultivation process starting from the transition to organic stock material through to harvest and packaging, and will evaluate the successful execution of Organigram’s action plan. These inspections will confirm the company’s compliance with the organic standards: CAN/CSGB 32.310(2015)- General Principles and Management Standards and the CAN/CSGB 32.311(2015)- Permitted Substances Lists.
The company will work diligently to complete the re-certification process before July 2018.
For more information, visit www.Organigram.ca.
About Organigram Holdings Inc.
Organigram Holdings Inc. is a TSX Venture Exchange listed company whose wholly owned subsidiary, Organigram Inc., is a licensed producer of medical marijuana in Canada. Organigram is focused on producing the highest quality, condition specific medical marijuana for patients in Canada. Organigram's facility is located in Moncton, New Brunswick and the Company is regulated by the Access to Cannabis for Medical Purposes Regulations (“ACMPR”).
Organigram has been ranked in the top ten Clean Technology & Life Sciences Sector on the TSX Venture Exchange 50.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This news release contains forward-looking information which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectations. Important factors - including the availability of funds, consummation of definitive documentation, the results of financing efforts, crop yields - that could cause actual results to differ materially from the Company's expectations are disclosed in the Company's documents filed from time to time on SEDAR (see www.sedar.com). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
For further information, please contact:
Organigram Holdings Inc.
Greg Engel
Chief Executive Officer
gengel@organigram.ca
(416) 435-8091 Organigram Holdings Inc.
Giselle Doiron
Director of Investor Relations & Media
investorrelations@organigram.ca
(506) 801-8986
Recent OGI News
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/08/2024 03:29:51 PM
- Organigram to Report Second Quarter Fiscal 2024 Results on May 14, 2024 • Business Wire • 05/08/2024 12:00:00 PM
- Organigram Recognized for Executive Gender Diversity by the Globe & Mail’s Women Lead Here Report for the Fourth Consecutive Year • Business Wire • 04/08/2024 10:00:00 AM
- Organigram’s Popular SHRED Brand Surpasses $200 Million in Yearly Retail Sales • Business Wire • 04/03/2024 12:06:00 PM
- Organigram Successfully Closes Previously Announced Underwritten Public Offering • Business Wire • 04/02/2024 12:51:00 PM
- Organigram Announces Pricing of Overnight Marketed Public Offering • Business Wire • 03/27/2024 12:56:00 PM
- Organigram Announces Launch of Overnight Marketed Public Offering • Business Wire • 03/26/2024 11:06:00 PM
- Organigram Invests in U.S. Based Open Book Extracts Representing Inaugural Jupiter Investment • Business Wire • 03/26/2024 05:36:00 PM
- Organigram Receives Health Canada’s Final Redetermination on Jolts • Business Wire • 03/22/2024 11:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/28/2024 03:42:13 PM
- Organigram Applauds the Standing Committee on Finance’s Recommendation on Excise Duty • Business Wire • 02/28/2024 01:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/13/2024 12:23:18 PM
- Organigram Reports First Quarter Fiscal 2024 Results • Business Wire • 02/13/2024 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/07/2024 02:25:53 PM
- Organigram to Report First Quarter Fiscal 2024 Results on February 13, 2024 • Business Wire • 02/07/2024 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/31/2024 01:36:42 PM
- Organigram Completes First Shipment to Germany, Extending its International Reach • Business Wire • 01/31/2024 11:00:00 AM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 01/25/2024 10:23:26 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/24/2024 10:30:11 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/24/2024 02:23:37 PM
- Organigram Announces the First Tranche Closing from BAT Investment • Business Wire • 01/24/2024 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/19/2024 12:38:06 PM
- Organigram Announces Appointment of Karina Gehring to Board of Directors • Business Wire • 01/19/2024 11:00:00 AM
- Organigram Announces Results of Annual and Special Meeting, including Shareholder Approval of C$124.6 Million Investment from BAT • Business Wire • 01/19/2024 01:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/29/2023 12:25:46 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM